Skip to main content

Table 1 Demographics and patient characteristics (intent-to-treat population)

From: Efficacy, adherence and tolerability of once daily tenofovir DF-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment: results of a 48-week open-label study

Parameter Naïve (N = 27) Restart (N = 30) Switch (N = 10) Total (N = 67)
Sex; n (%) male 17 (63%) 22 (73%) 6 (60%) 45 (67%)
Age (years); median [range] 34 [23-49] 38.5 [26-54] 40.5 [31-49] 37 [23-54]
BMI (kg/m2); median [range] 21.77 [15.6-30.9] 21.90 [13.1-32.2] 24.44 [17.0-34.1] 22.13 [13.1-34.1]
Time since onset infection (years); median [range] 4.79 [0.1-23.8] 9.18 [2.4-19.3] 12.41 [3.6-16.3] 8.70 [0.1-23.8]
HIV-1 RNA ≥ 400 copies/mL; n (%) 24 (89%)1 28 (93%)1 0 (0%) 52 (81%)1
HIV-1 RNA (log10 copies/mL); median [IQR] 5.00 [4.7-5.6] 4.70 [4.1-5.3] 1.69 [1.69-1.69] 4.70 [3.50-5.21]
CD4+ cell count (cells/mm3); median [IQR] 193 [54-256] 169 [91-285] 436 [289-694] 207 [100-297]
CD8+ cell count (cells/mm3); median [IQR] 592 [445-1059] 879 [437-1329] 870 [490-1129] 764 [442-1190]
Antiretroviral medications started at baseline as part of combination regimen
NRTI; n/N (%)     67/67 (100)
Tenofovir disoproxil fumarate (TDF); n (%) 27/27 (100) 30/30 (100) 10/10 (100) 67/67 (100)
Emtricitabine or Lamivudine (FTC/3TC) 27/27 (100) 27/30 (90) 10/10 (100) 64/67 (96)
Didanosine (DDI) 0 3/30 (10) 1/10 (10) 4/67 (6)
Tenofovir disoproxil fumarate - - - 67/67 (100)
Emtricitabine - - - 47/67 (70)
Lamivudine - - - 15/67 (22)
PI; n/N (%) - - - 55/67 (82)
Atazanavir/Ritonavir (ATV/r) 19/27 (70) 22/30 (73) 8/10 (80) 49/67 (73)
Atazanavir 1/27 (4) 4/30 (13) 1/10 (10) 6/67 (9)
NNRTI; n/N (%) - - - 11/67 (16)
Efavirenz (EFV) 5/27 (19) 2/30 (7) 0 7/67 (10)
Nevirapine (NVP) 2/27 (7) 2/30 (7) 0 4/67 (6)
Regimen: n/N (%)     
PI + NRTI 20/27 (74) 26/30 (87) 9/10 (90) 55/67 (82)
TDF + FTC or 3TC + ATV/r 19/27 (70) 19/30 (63) 8/10 (80) 46/67 (69)
TDF + FTC or 3TC + ATV 1/27 (4) 4/30 (13) 1/10 (10) 6/67 (9)
TDF + DDI + ATV/r 0 3/30 (10%) 0 3/67 (4)
NNRTI + NRTI; n (%) 7/27 (26) 4/30 (13) 0 11/67 (16)
TDF + FTC or 3TC + EFV 5/27 (19) 2/30 (7) 0 7/67 (10)
TDF + FTC or 3TC + NVP 2/27 (7) 2/30 (7) 0 4/67 (6)
All NRTI; n (%) 0 0 1/10 (10) 1/67 (1)
TDF + FTC or 3TC + DDI    1/10 (10) 1/67 (1)
Opiate treatment at screening
Time since onset opiate treatment (years); median [range] 3.01 [0.1-11.7] 6.03 [0.00-24.7] 8.24 [0.2-18.1] 5.26 [0.0-24.7]
Time since start stable dose (years); median [range] - - - 1.6 [0-11.7]
Opiate treatment dose (mg); mean (SD)     
Methadone (n = 57; 85%) 84.1 (33.31) 98.2 (49.47) 70.0 (62.29) 88.8 (44.5 mg)
Levomethadone (n = 9; (13%) 70.02 12.0 (20.41) 73.8 (39.45) 93.9 (36.8 mg)
Buprenorphine (n = 1; 1%) - 12.0 - 12.02
  1. BMI = body mass index; IQR = interquartile range; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor;
  2. NNRTI = non-nucleoside reverse transcriptase inhibitor
  3. 1Three patients had no HIV-1 RNA plasma concentration available at baseline, two patients in the treatment-naive subgroup and one in the restart subgroup; 2n = 1
Back to article page

European Journal of Medical Research

ISSN: 2047-783X

Contact us